NCT05913921View on ClinicalTrials.gov

Bioequivalence of Amphotericin B Liposome for Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions
Bioequivalence
Interventions
DRUG

Amphotericin B liposome for injection

IV infusion, 2.0 mg/kg

DRUG

AmBisome

IV infusion, 2.0 mg/kg

Trial Locations (1)

Unknown

Haikou people's Hospital, Haikou

All Listed Sponsors
lead

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

INDUSTRY

NCT05913921 - Bioequivalence of Amphotericin B Liposome for Injection | Biotech Hunter | Biotech Hunter